管科系系列讲座第236期预告

时 间:2019年5月30日(周五)10:00

地 点:史带楼301

主持人:陈祥锋教授

主讲嘉宾: Hui Zhang is the Associate Professor at Faculty of Business Administration, Lakehead University in Canada.

TitleRewarding or penalizing to improve the adherence to a drug: an economic analysis of risk-sharing agreements

Abstract: With rising concerns of limited health care budget, more and more third-party payers are using different mechanisms to control drug costs and improve treatment outcomes. Risk-sharing agreements are very popular forms of mechanisms in which payers sign contracts with drug makers to share financial or performance risks. The financial risks are caused by uncertainties on drug usage, while the performance risks are caused by uncertain health outcome of a treatment. In this paper, I am considering an innovative form of risk-sharing agreement in which a drug maker provides a discount to the payer if the drug utilization exceeds a certain criterion. It is the opposite to a traditional performance-based risk-sharing, in which a drug maker provides a discount if the drug performance is below a certain standard. This agreement is motivated by the concerns of low persistence/adherence level of patients with chronic diseases such as diabetes. In this agreement, if the payer’s subscribers can improve their adherence of taking the prescribed medication from the drug maker compared to the baseline level of the payer’s whole population, then a discount will be provided by the drug maker. Both the payer and the drug maker can benefit out of this agreement: the payer can have more patients being cured and the drug maker can sell more drugs. Therefore, both the payer and the drug maker have incentives to promote the adherence of patients to prescriptions via some venues like patient-compliance programs. This paper focuses on how a patient-compliance program should be run by the payer and by the drug maker and what are the differences. I also compare this new form of risk-sharing with the traditional form of risk-sharing and investigate their impacts on the patient-compliance program effort by both parties. Analytical results will be provided and numerical experiments will be conducted to provide managerial insights to health care decision-makers on improving patients’ drug adherence and health outcomes.


管理科学系

2019-5-16